Skip to main content
Have a personal or library account? Click to login
Methods of amorphization and investigation of the amorphous state Cover

Methods of amorphization and investigation of the amorphous state

Open Access
|Oct 2013

References

  1. 1. B. C. Hancock and G. Zografi, Characteristics and significance of the amorphous state in pharmaceutical systems,(1997) 1-12; DOI: 10.1021/js9601896.
  2. 2. L. Yu, Amorphous pharmaceutical solids: preparation, characterization and stabilization,(2001) 27-42; DOI: 10.1016/S0169-409X(01)00098-9.
  3. 3. G. L. Amidon, H. Lennernäs, V. P. Shah and J. R. Crison, A theoretical basis for a biopharmaceutic drug classification: the correlation ofdrug product dissolution andbioavailability,(1995) 413-420; DOI: 10.1023/A:1016212804288.
  4. 4. P. Poole, T. Grande, C. Angell and P. McMillan, Polymorphic phase transitions in liquids and glasses,(1997) 322-323; DOI: 10.1126/science.275.5298.322.
  5. 5. A. Saleki-Gerhardt, J. G. Stowell, S. R. Byrn and G. Zografi, Hydration and dehydration of crystalline and amorphous forms of raffinose,(1995) 318-323.
  6. 6. L. R. L. Hilden and K. R. K. Morris, Physics of amorphous solids,(2003) 3-12; DOI: 10.1002/jps.10489.
  7. 7. K. A. Graeser, C. J. Strachan, J. E. Patterson, K. C. Gordon and T. Rades, Physicochemical properties and stability of two differently prepared amorphous forms of simvastatin,(2008) 128-135; DOI: 10.1021/cg700913m.
  8. 8. P. Karmwar, K. Graeser, K. C. Gordon, C. J. Strachan and T. Rades, Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods,(2011) 94-100; DOI: 10.1016/j.ijpharm.2010.12.019.
  9. 9. M. Otsuka, J.-I. Nishizawa, N. Fukura and T. Sasaki, Characterization of poly-amorphous indomethacin by terahertz spectroscopy,(2012) 953-962; DOI: 10. 1007/s10762-012-9910-1.
  10. 10. R. Lefort, A. De Gusseme, J. F. Willart, F. Danède and M. Descamps, Solid state NMR and DSC methods for quantifying the amorphous content in solid dosage forms: an application to ball- -milling of trehalose,(2004) 209-219; DOI: 10.1016/j.ijpharm.2004.05.012.
  11. 11. D. Kivelson, J. Pereda, K. Luu, M. Lee, H. Sakai, A. Ha, I. Cohen and G. Tarjus, Facts and speculation concerning low-temperature polymorphism in glass formers,(1997), 224-232; DOI: 10.1021/bk-1997-0676.ch017.
  12. 12. J. E. Patterson, M. B. James, A. H. Forster, R. W. Lancaster, J. M. Butler and T. Rades, The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds,(2005) 1998-2012; DOI: 10.1002/jps.20424.
  13. 13. D. Q. D. Craig, V. L. V. Kett, J. R. J. Murphy and D. M. D. Price, The measurement of small quantities of amorphous material-should we be considering the rigid amorphous fraction,(2001) 1081-1082.
  14. 14. D. Turnbull, Under what conditions can a glass be formed?,(1969) 473-488; DOI: 10.1080/00107516908204405.
  15. 15. C. Angell, Structural instability and relaxation in liquid and glassy phases near the fragile liquid limit,(1988) 205-221; DOI: 10.1016/0022-3093(88)90133-0.
  16. 16. J. Liu, D. Rigsbee, C. Stotz and M. Pikal, Dynamics of pharmaceutical amorphous solids: The study of enthalpy relaxation by isothermal microcalorimetry,(2002) 1853-1862; DOI:10.1002/jps.10181.
  17. 17. D. Grant,, Marcel Dekker, Basel 1999, pp. 183-227.
  18. 18. K. A. Graeser, J. E. Patterson, J. A. Zeitler, K. C. Gordon and T. Rades, Correlating thermodynamic and kinetic parameters with amorphous stability,(2009) 492-498; DOI: 10.1016/j.ejps.2009.04.005.
  19. 19. J. W. Lee, L. C. Thomas and S. J. Schmidt, Effects of heating conditions on the glass transition parameters of amorphous sucrose produced by melt-quenching,(2011) 3311-3319; DOI: 10.1021/jf104853s.
  20. 20. H. Miyanishi, T. Nemoto, M. Mizuno, H. Mimura, S. Kitamura, Y. Iwao, S. Noguchi and S. Itai, Evaluation of crystallization behavior on the surface of nifedipine solid dispersion powder using inverse gas chromatography,(2013) 502-511; DOI: 10.1007/s11095-012-0896-0.
  21. 21. M. G. Abiad, D. C. Gonzalez, B. Mert, O. H. Campanella and M. T. Carvajal, A novel method to measure the glass and melting transitions of pharmaceutical powders,(2010) 23-29; DOI: 10.1016/j.ijpharm.2010.06.001.
  22. 22. H. Takeuchi, S. Nagira, H. Yamamoto and Y. Kawashima, Solid dispersion particles of tolbutamide prepared with fine silica particles by the spray-drying method,(2004) 187-195; DOI: 10.1016/j,powtec.2004.03.007.
  23. 23. R. C. Rowe, P. J. Sheskey, W. G. Cook and M. F. Fenton,, inPharmaceutical Press, London 2000, pp. 143-145.
  24. 24. H. Takeuchi, T. Handa and Y. Kawashima, Spherical solid dispersion containing amorphous tolbutamide embedded in enteric coating polymers or colloidal silica prepared by spray-drying technique,(1987) 3800-3806.
  25. 25. I. Chuang and G. Maciel, Probing hydrogen bonding and the local environment of silanols on silica surfaces via nuclear spin cross polarization dynamics,(1996) 401-406; DOI: 10.1021/ja951550d.
  26. 26. J. Broadhead, S. K. E. Rouan and C. T. Rhodes, The spray drying of pharmaceuticals,(1992) 11-12; DOI: 10.3109/03639049209046327.
  27. 27. R. Vehring, Pharmaceutical particle engineering via spray drying,(2008) 999-1022; DOI: 10.1007/s11095-007-9475-1.
  28. 28. K. Haque and Y. H. Roos, Crystallization and X-ray diffraction of spray-dried and freeze-dried amorphous lactose,(2005) 293-301; DOI: 10.1016/j.carres.2004.11.026.
  29. 29. D. Chiou, T. A. G. Langrish and R. Braham, The effect of temperature on the crystallinity of lactose powders produced by spray drying,288-293; DOI: 10.1016/j.jfoodeng.2007. 10.005.
  30. 30. S. P. Bhardwaj, K. K. Arora, E. Kwong, A. Templeton, S. D. Clas and R. Suryanarayanan, Correlation between molecular mobility and physical stability of amorphous itraconazole,(2013) 694-700; DOI: 10.1021/mp300487u.
  31. 31. M. Vogt, K. Kunath and J. B. Dressman, Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations,(2008) 283-288; DOI: 10.1016/j.ejpb.2007.05.010.
  32. 32. D. Q. Craig, P. G. Royall, V. L. Kett and M. L. Hopton, The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems,(1999) 179-207; DOI: 10.1016/S0378-5173(98)00338-X.
  33. 33. J. Liu, Physical characterization of pharmaceutical formulations in frozen and freeze-dried solid states: techniques and applications in freeze-drying development,(2006) 3-28; DOI: 10.1080/10837450500463729.
  34. 34. S. P. Bhardwaj and R. Suryanarayanan, Molecular mobility as an effective predictor of the physical stability of amorphous trehalose,(2012) 3209-3217; DOI: 10.1021/mp300302g.
  35. 35. K. P. O’Donnell, Z. Cai, P. Schmerler and R. O. I. Williams, Atmospheric freeze drying for the reduction of powder electrostatics of amorphous, low density, high surface area pharmaceutical powders,(2013) 205-217; DOI: 10.3109/03639045.2012.669385.
  36. 36. Y. Li, J. Han, G. G. Zhang, D. J. Grant and R. Suryanarayanan, In situ dehydration of carbamazepine dihydrate: a novel technique to prepare amorphous anhydrous carbamazepine,(2000) 257-266; DOI: 10.1081/PDT-100100540.
  37. 37. F. Sussich and A. Cesaro, Trehalose amorphization and recrystallization,2667-2674; DOI: 10.1016/j.carres.2008.08.008.
  38. 38. B. Bennett and G. Cole,, IChemE 2003, pp. 111-201.
  39. 39. D. M. Parikh,Taylor and Francis, London 2005, pp. 491-512.
  40. 40. R. Liu,, Taylor and Francis, London 2008, pp. 88-455.
  41. 41. R. Price and P. M. Young, On the physical transformations of processed pharmaceutical solids,(2005) 519-524; DOI: 10.1016/j.micron.2005.04.003.
  42. 42. G. Zhang, C. Gu, M. Zell, R. Burkhardt, E. Munson and D. Grant, Crystallization and transitions of sulfamerazine polymorphs,(2002) 1089-1100; DOI: 10.1002/jps.10100.
  43. 43. P. Thanatuksorn, K. Kawai, K. Kajiwara and T. Suzuki, Effects of ball-milling on the glass transition of wheat flour constituents,(2009) 430-435; DOI: 10.1002/jsfa.3463.
  44. 44. J. F. Willart and M. Descamps, Solid state amorphization of pharmaceuticals,(2008) 905-920; DOI: 10.1021/mp800092t.
  45. 45. A. Revesz, Melting behavior and origin of strain in ball-milled nanocrystalline Al powders,(2005) 1643-1646; DOI: 10.1007/s10853-005-0664-1.
  46. 46. S. Karki, T. Friscic, W. Jones and W. D. S. Motherwell, Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding,(2007) 347-354; DOI: 10. 1021/mp0700054.
  47. 47. K. Chadwick, R. Davey and W. Cross, How does grinding produce co-crystals? Insights from the case of benzophenone and diphenylamine,(2007) 732-734; DOI: 10.1039/ b709411f.
  48. 48. T. Shakhtshneider, Phase transformations and stabilization of metastable states of molecular crystals under mechanical activation,(1997) 851-856; DOI: 10.1016/S0167-2738(97)00224-5.
  49. 49. E. Dudognon, J. Willart, V. Caron, F. Capet, T. Larsson and M. Descamps, Formation of budesonide/ alpha-lactose glass solutions by ball-milling,(2006) 68-71; DOI: 10.1016/j.ssc.2006.02.007.
  50. 50. I. Tsukushi, O. Yamamuro and T. Matsuo, Solid state amorphization of organic molecular crystals using a vibrating mill,(1995) 1013-1013; DOI: 10.1016/0038-1098 (95)00161-1.
  51. 51. J. Font, J. Muntasell and E. Cesari, Amorphization of organic compounds by ball milling,(1997) 1691-1696; DOI: 10.1016/S0025-5408(97)00162-1.
  52. 52. J. Willart, V. Caron, R. Lefort, F. Danède, D. Prevost and M. Descamps, Athermal character of the solid state amorphization of lactose induced by ball milling,(2004) 693-696; DOI: 10.1016/j.ssc.2004.09.007.
  53. 53. M. Otsuka, H. Ohtani, N. Kaneniwa and S. Higuchi, Isomerization of lactose in solid-state by mechanical stress during grinding,(1991) 148-153; DOI: 10.1111/j.2042-7158.1991.tb06656.x.
  54. 54. J. Willart, A. De Gusseme, S. Hemon, G. Odou, F. Danède and M. Descamps, Direct crystal to glass transformation of trehalose induced by ball milling,(2001) 501-505; DOI: 10.1016/S0038-1098(01)00283-6.
  55. 55. A. J. Megarry, J. Booth and J. Burley, Amorphous trehalose dihydrate by cryogenic milling,(2011) 1061-1064; DOI: 10.1016/j.carres.2011.03.011.
  56. 56. J. F. Willart, N. Dujardin, E. Dudognon, F. Danède and M. Descamps, Amorphization of sugar hydrates upon milling,(2010) 1613-1616; DOI: 10.1016/j.carres.2010.04.014.
  57. 57. P. Okamoto and N. Lam, Physics of crystal-to-glass transformations,(1999) 1-135; DOI: 10.1016/S0081-1947(08)60018-1.
  58. 58. H. Fecht, Defect-induced melting and solid-state amorphization,(1992) 133-135; DOI: 10.1016/S0081-1947(08)60018-1.
  59. 59. M. Descamps, J. F. Willart, E. Dudognon and V. Caron, Transformation of pharmaceutical compounds upon milling and comilling: the role ofg,(2007) 1398-1407; DOI: 10. 1002/jps.20939.
  60. 60. J. Willart, N. Descamps, V. Caron, F. Capet, F. Danède and M. Descamps, Formation of lactose- -mannitol molecular alloys by solid state vitrification,(2006) 194-199; DOI: 10.1016/j.ssc.2006.02.034.
  61. 61. G. Martin and P. Bellon, Driven alloys,(1997) 189-331.
  62. 62. S. Qi, I. Weuts, S. De Cort, S. Stokbroekx, R. Leemans, M. Reading, P. Belton and D. Q. M. Craig, An investigation into the crystallisation behaviour of an amorphous cryomilled pharmaceutical material above and below the glass transition temperature,(2010) 196-208; DOI: 10.1002/jps.21811.
  63. 63. K. J. Crowley and G. Zografi, Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability,(2002) 492-507; DOI: 10.1002/jps.10028.
  64. 64. J. Carstensen,Marcel Dekker, New York 2001, pp. 107-117.
  65. 65. C. Sun and D. J. Grant, Influence of crystal shape on the tableting performance of L-lysine monohydrochloride dihydrate,(2001) 569-579; DOI: 10.1002/1520-6017(200105)90: 5<569::AID-JPS1013>3.0.CO;2-4.
  66. 66. V. Chikhalia, R. T. Forbes, R. A. Storey and M. Ticehurst, The effect of crystal morphology and mill type on milling induced crystal disorder,(2006) 19-26; DOI: 10.1016/ j.ejps.2005.08.013.
  67. 67. T. Watanabe, S. Hasegawa, N. Wakiyama, A. Kusai and M. Senna, Comparison between polyvinylpyrrolidone and silica nanoparticles as carriers for indomethacin in a solid state dispersion,(2003) 283-286; DOI: 10.1016/S0378-5173(02)00549-5.
  68. 68. A. Ali, K. Yamamoto, A. Elsayed, F. Habib and Y. Nakai, Molecular behavior of flufenamic acid in physical and ground mixtures with florite,(1992) 1289-1294.
  69. 69. H. Sekizaki, K. Danjo, H. Eguchi, Y. Yonezawa, H. Sunada and A. Otsuka, Solid-state interaction of ibuprofen with polyvinylpyrrolidone,(1995) 988-993.
  70. 70. V. Boldyrev, T. Shakhtshneider, L. Burleva and V. Severstev, Preparation of the disperse systems of sulfathiazole-polyvinylpyrrolidone by mechanical activation,(1994) 1103-1114.
  71. 71. N. Kaneniwa and A. Ikekava, Solubilization of Water-insoluble organic powders by ball-milling in the presence of polyvinylpyrrolidone,(1975) 2973-2986.
  72. 72. N. Kaneniwa, A. Ikekava and M. Sumi, A decrease in crystallinity of amobarbital by mechanical treatment in presence of diluents,(1978) 2734-2743.
  73. 73. H. Takeuchi, S. Nagira, H. Yamamoto and Y. Kawashima, Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method,(2005) 155-164; DOI: 10.1016/j.ijpharm.2004.12.019.
  74. 74. M. Fujii, H. Okada, Y. Shibata, H. Teramachi, M. Kondoh and Y. Watanabe, Preparation, characterization, and tableting of a solid dispersion of indomethacin with crospovidone,(2005) 145-153; DOI: 10.1016/j.ijpharm.2004.12.018.
  75. 75. Y. Nakai, E. Fukuoka, S. Nakajima and Y. Iida, Effect of grinding on physical and chemical properties of crystalline medicinals with microcrystalline cellulose. 2. Retention of volatile medicinals in ground mixture,(1978) 2983-2989.
  76. 76. M. Cirri, F. Maestrelli, S. Furlanetto and P. Mura, Solid-state characterization of glyburide-cyclodextrin co-ground products,(2004) 413-422; DOI: 10.1023/B: JTAN.0000038982.40315.8f.
  77. 77. T. Shakhtshneider, M. Vasiltchenko, A. Politov and V. Boldyrev, The mechanochemical preparation of solid disperse systems of ibuprofen-polyethylene glycol,(1996) 25-32; DOI: 10.1016/0378-5173(95)04244-X.
  78. 78. D. Bahl and R. H. Bogner, Amorphization of indomethacin by co-grinding with Neusilin US2: Amorphization kinetics, physical stability and mechanism,(2006) 2317-2325; DOI: 10.1007/s11095-006-9062-x.
  79. 79. U. Zimper, J. Aaltonen, C. M. McGoverin, K. C. Gordon, K. Krauel-Goellner and T. Rades, Quantification of process induced disorder in milled samples using different analytical techniques,(2010) 30-49; DOI: 10.3390/pharmaceutics2010030.
  80. 80. V. Caron, J. F. Willart, R. Lefort, P. Derollez, F. Danède and M. Descamps, Solid state amorphization kinetic of alpha lactose upon mechanical milling,(2011) 2622-2628; DOI: 10.1016/j.carres.2011.09.004.
  81. 81. J. P. Bøtker, P. Karmwar, C. J. Strachan, C. Cornett, F. Tian, Z. Zujovic, J. Rantanen and T. Rades, Assessment of crystalline disorder in cryo-milled samples of indomethacin using atomic pair- -wise distribution functions,(2011) 112-119; DOI: 10.1016/j.ijpharm.2010.12. 018.
  82. 82. K. Terada, H. Kitano, Y. Yoshihashi and E. Yonemochi, Quantitative correlation between initial dissolution rate and heat of solution of drug,(2000) 920-924; DOI: 10.1023/A: 1007514902161
  83. 83. Z. Lavrič, J. Pirnat, J. Lužnik, J. Seliger, V. Žagar, Z. Trontelj and S. Srcic, Application of 14N NQR to the study of piroxicam polymorphism,(2010) 4857-4865; DOI: 10.1002/ jps.22186.
  84. 84. C. J. Strachan, T. Rades and K. C. Gordon, A theoretical and spectroscopic study of gamma- -crystalline and amorphous indomethacin,(2007) 261-269; DOI: 10.1211/ jpp.59.2.0012.
  85. 85. M. Savolainen, A. Heinz, C. Strachan, K. C. Gordon, J. Yliruusi, T. Rades and N. Sandler, Screening for differences in the amorphous state of indomethacin using multivariate visualization,(2007) 113-123; DOI: 10.1016/j.ejps.2006.10.010.
  86. 86. C. Rawle, C. Lee, C. Strachan, K. Payne, P. Manson and T. Rades, Towards characterization and identification of solid state pharmaceutical mixtures through second harmonic generation,(2006) 761-768; DOI: 10.1002/jps.20575.
  87. 87. G. G. Buckton and P. P. Darcy, Assessment of disorder in crystalline powders - a review of analytical techniques and their application,(1999) 141-158; DOI: 10.1016/S0378-5173(98)00335-4.
  88. 88. B. Shah, V. K. Kakumanu and A. K. Bansal, Analytical techniques for quantification of amorphous/ crystalline phases in pharmaceutical solids,(2006) 1641-1665; DOI: 10. 1002/jps.20644.
  89. 89. N. Chieng, Z. Zujovic, G. Bowmaker, T. Rades and D. Saville, Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1,(2006) 36-44; DOI: 10.1016/j.ijpharm.2006.07.032.
  90. 90. C. Gustafsson, H. Lennholm, T. Iversen and C. Nyström, Comparison of solid-state NMR and isothermal microcalorimetry in the assessment of the amorphous component of lactose,(1998) 243-252; DOI: 10.1016/S0378-5173(98)00272-5.
  91. 91. M. Mirmehrabi, S. Rohani, K. S. K. Murthy and B. Radatus, Characterization of tautomeric forms of ranitidine hydrochloride: thermal analysis, solid-state NMR, X-ray,(2004) 517-526; DOI: 10.1016/j.jcrysgro.2003.08.061.
  92. 92. D. C. Apperley, R. A. Fletton, R. K. Harris, R. W. Lancaster, S. Tavener and T. L. Threlfall, Sulfathiazole polymorphism studied by magic-angle spinning NMR,(1999) 1275-1280; DOI: 10.1021/js990175a.
  93. 93. D. C. Apperley, R. K. Harris, T. Larsson and T. Malmstrom, Quantitative nuclear magnetic resonance analysis of solid formoterol fumarate and its dihydrate,(2003) 2487-2494; DOI: 10.1002/jps.10500.
  94. 94. P. A. Tishmack, D. E. Bugay and S. R. Byrn, Solid-state nuclear magnetic resonance spectroscopy- pharmaceutical applications,(2003) 441-474; DOI: 10.1002/jps.10307.
  95. 95. A. Gombás, I. Antal, P. Szabó-Révész, S. Marton and I. Erõs, Quantitative determination of crystallinity of alpha-lactose monohydrate by near Infrared Spectroscopy (NIRS),(2003) 25-32; DOI: 10.1016/S0378-5173(03)00059-0.
  96. 96. P. Debenedetti,, Princeton University Press, Chichester 1996.
  97. 97. G. P. Johari, S. Ram, G. Astl and E. Mayer, Characterizing amorphous and microcrystalline solids by calorimetry,(1990) 282-285; DOI: 10.1016/0022-3093(90)90703-O.
  98. 98. S. Bates, G. Zografi, D. Engers, K. Morris, K. Crowley and A. Newman, Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns,(2006) 2333-2349; DOI: 10.1007/s11095-006-9086-2.
  99. 99. S. J. L. Billinge and M. G. Kanatzidis, Beyond crystallography: the study of disorder, nanocrystallinity and crystallographically challenged materials with pair distribution functions,(2004) 749-760; DOI: 10.1039/b309577k..
  100. 100. A. S. Masadeh, E. S. Bozin, C. L. Farrow, G. Paglia, P. Juhas, S. J. L. Billinge, A. Karkamkar and M. G. Kanatzidis, Quantitative size-dependent structure and strain determination of CdSe nanoparticles using atomic pair distribution function analysis,(2007); DOI: 10. 1103/PhysRevB.76.115413.
  101. 101. T. Egami and S. J. L. Billinge,, Pergamon Press, Oxford 2003, pp. 25-101.
  102. 102. T. Proffen, S. Billinge, T. Egami and D. Louca, Structural analysis of complex materials using the atomic pair distribution function - a practical guide,(2003) 132-143; DOI: 10.1524/zkri.218.2.132.20664.
  103. 103. L. Tarasov and B. E. Warren, X-ray diffraction study of liquid sodium,(1936) 236-238; DOI: 10.1063/1.1749828.
  104. 104. B. Warren, H. Krutter and O. Morningstar, Fourier-analysis of X-ray-patterns of vitreous SiO2 and B2O3,(1992) 11-15.
  105. 105. F. Zernike and J. A. Prins, Die Beugung von Röntgenstrahlen in Flüssigkeiten als Effekt der Molekülanordnung,(1927) 184-194; DOI: 10.1007/BF01391926.
  106. 106. F. Atassi, C. Mao, A. S. Masadeh and S. R. Byrn, Solid-state characterization of amorphous and mesomorphous calcium ketoprofen,(2009) 3684-3697; DOI: 10.1002/jps.21925.
  107. 107. S. Bates, R. C. Kelly, I. Ivanisevic, P. Schields, G. Zografi and A. W. Newman, Assessment of defects and amorphous structure produced in raffinose pentahydrate upon dehydration,(2007) 1418-1433; DOI: 10.1002/jps.20944.
  108. 108. A. Heinz, C. J. Strachan, F. Atassi, K. C. Gordon and T. Rades, Characterizing an amorphous system exhibiting trace crystallinity: A case study with saquinavir,(2008) 119-127; DOI: 10.1021/cg700912q.
  109. 109. A. Sheth, S. Bates, F. Muller and D. Grant, Polymorphism in piroxicam,(2004) 1091-1098; DOI: 10.1021/cg049876y.
  110. 110. A. Sheth, S. Bates, F. Muller and D. Grant, Local structure in amorphous phases of piroxicam from powder X-ray diffractometry,(2005) 571-578; DOI: 10.1021/cg049757i.
  111. 111. M. D. Moore, A. M. Steinbach, I. S. Buckner and P. L. Wildfong, A structural investigation into the compaction behavior of pharmaceutical composites using powder X-ray diffraction and total scattering analysis,(2009) 2429-2437; DOI: 10.1007/s11095-009-9954-7.
  112. 112. A. Newman, D. Engers, S. Bates, I. Ivanisevic, R. C. Kelly and G. Zografi, Characterization of amorphous API: Polymer mixtures using X-ray powder diffraction,(2008) 4840-4856; DOI: 10.1002/jps.21352.
  113. 113. K. Nollenberger, A. Gryczke, C. Meier, J. Dressman, M. U. Schmidt and S. Brühne, Pair distribution function X-ray analysis explains dissolution characteristics of felodipine melt extrusion products,(2009) 1476-1486; DOI: 10.1002/jps.21534.
  114. 114. P. Robinson,ESTAC8 Abstract Book, Barcelona (August 25-29, 2002), p. 101.
  115. 115. Y. Roos, Melting and glass transitions of low molecular weight carbohydrates,(1993) 39-48; DOI: 10.1016/0008-6215(93)87004-C.
  116. 116. M. Brown,, Kluwer Academic Publishers, Amsterdam 2001.
  117. 117. Perkin Elmer,, Application Example PETAN-51, Norwalk 2000.
  118. 118. P. Claudy, M. Siniti and J. El Hajri, Thermodynamic study of the glass relaxation phenomena - DSC study of annealing of maltitol glass,(2002) 251-264.
  119. 119. M. J. Pikal, A. L. Lukes, J. E. Lang and K. Gaines, Quantitative crystallinity determinations for b-lactam antibiotics by solution calorimetry: Correlations with stability,(1978) 767-773; DOI: 10.1002/jps.2600670609.
  120. 120. D. Gao and J. Rytting, Use of solution calorimetry to determine the extent of crystallinity of drugs and excipients,(1997) 183-192; DOI: 10.1016/S0378-5173(97)04895-3.
  121. 121. S. E. Hogan and G. Buckton, The quantification of small degrees of disorder in lactose using solution calorimetry,(2000) 57-64; DOI: 10.1016/S0378-5173(00)00527-5.
  122. 122. K. C. Thompson, J. P. Draper, M. J. Kaufman and G. S. Brenner, Characterization of the crystallinity of drugs: B02669, a case study,.(1994) 1362-1365; DOI: 10.1023/A:101 8919201058.
  123. 123. G. H. Ward and R. K. Schultz, Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability,(1995) 773-779; DOI: 10.1023/A:1016232230 638.
  124. 124. P. Harjunen, V. P. Lehto, M. Koivisto, E. Levonen, P. Paronen and K. Järvinen, Determination of amorphous content of lactose samples by solution calorimetry,(2004) 809-815; DOI: 10.1081/DDC-200030302.
  125. 125. R. W. Douglas and G. A. Jones, An apparatus for the determination of small changes in density,(1947) 72; DOI: 10.1088/0950-7671/24/3/304.
  126. 126. J. Pelsmaekers and S. Amelinckx, Simple apparatus for comparative density measurements,(1961) 828-830; DOI: 10.1063/1.1717522.
  127. 127. R. Suryanarayanan, Evaluation of two concepts of crystallinity using calcium gluceptate as a model compound,(1985) 1-17; DOI: 10.1016/0378-5173(85)90140-1.
  128. 128. G. M. Venkatesh, M. E. Barnett, C. Owusu-Fordjour and M. Galop, Detection of low levels of the amorphous phase in crystalline pharmaceutical materials by thermally stimulated current spectrometry,(2001) 98-103, DOI: 10.1023/A:1011087012826.
  129. 129. R. Huttenrauch, Molecular galenics as the basis of modern drug formation,(Suppl.)(1978) 55-127
  130. 130. A. Salekigerhardt, C. Ahlneck and G. Zografi, Assessment of disorder in crystalline solids,(1994) 237-247; DOI: 10.1016/0378-5173(94)90219-4.
  131. 131. P. M. Young, H. Chiou, T. Tee, D. Traini, H.-K. Chan, F. Thielmann and D. Burnett, The use of organic vapor sorption to determine low levels of amorphous content in processed pharmaceutical powders,(2007) 91-97; DOI: 10.1080/03639040600969991.
  132. 132. J. Vollenbroek, G. A. Hebbink, S. Ziffels and H. Steckel, Determination of low levels of amorphous content in inhalation grade lactose by moisture sorption isotherms,(2010) 62-70; DOI: 10.1016/j.ijpharm.2010.04.035.
  133. 133. M. Kunaver, J. Zadnik and O. Planinsek, Inverse gas chromatography-A different approach to characterization of solids and liquids,(2004) 373-394.
  134. 134. A. Voelkel, B. Strzemiecka, K. Adamska and K. Milczewska, Inverse gas chromatography as a source of physicochemical data,(2009) 1551-1566; DOI: 10.1016/j.chroma. 2008.10.096.
  135. 135. S. P. Chamarthy and R. Pinal, The nature of crystal disorder in milled pharmaceutical materials,(2008) 68-75; DOI: 10.1016/j.colsurfa.2008.06.040.
  136. 136. O. Planinsek, J. Zadnik, M. Kunaver, S. Srcic and A. Godec, Structural evolution of indomethacin particles upon milling: time-resolved quantification and localization of disordered structure studied by IGC and DSC,(2010) 1968-1981; DOI: 10.1002/jps.21986.
  137. 137. M. Otsuka and N. Kaneniwa, Effect of environment on crystallinity and chemical stability in solid-state of ground cephalotin sodium during storage,(1990) 909-918; DOI: 10.3109/03639049109040828.
  138. 138. H. Konno and L. S. Taylor, Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine,(2006) 2692-2705; DOI: 10.1002/ jps.20697.
  139. 139. X. C. Tang, M. J. Pikal and L. S. Taylor, The effect of temperature on hydrogen bonding in crystalline and amorphous phases in dihydropyrine calcium channel blockers,(2002) 484-490; DOI: 10.1023/A:1015199713635.
  140. 140. L. Mackin, S. Sartnurak, I. Thomas and S. Moore, The impact of low levels of amorphous material,(2002) 213-226; DOI: 10.1016/S0378-5173(01)00880-8.
  141. 141. J. J. Seyer, P. E. Luner and M. S. Kemper, Application of diffuse reflectance near-infrared spectroscopy for determination of crystallinity,(2000) 1305-1316; DOI: 10.1002/ 1520-6017(200010)89:10<1305::AID-JPS8>3.0.CO;2-Q.
  142. 142. S. J. Bai, M. Rani, R. Suryanarayanan, J. F. Carpenter, R. Nayar and M. C. Manning, Quantification of glycine crystallinity by near-infrared (NIR) spectroscopy,(2004) 2439-2447; DOI:10.1002/jps.20153.
  143. 143. P. Aldridge, C. Evans, H. Ward, S. Colgan, N. Boyer and P. Gemperline, Near-IR detection of polymorphism and process-related substances,(1996) 997-1002; DOI: 10.1021/ ac950993x.
  144. 144. S. Hogan and G. Buckton, The application of near infrared spectroscopy and dynamic vapor sorption to quantify low amorphous contents of crystalline lactose,(2001) 112-116; DOI: 10.1023/A:1011091113734.
  145. 145. G. Buckton, E. Yonemochi, J. Hammond and A. Moffat, The use of near infra-red spectroscopy to detect changes in the form of amorphous and crystalline lactose,(1998) 231-241; DOI: 10.1016/S0378-5173(98)00095-7.
  146. 146. M. Otsuka and H. Tanabe, Stability test for amorphous materials in humidity controlled 96- -well plates by near-infrared spectroscopy,(2012) 380-385; DOI: 10. 3109/03639045.2011.608680.
  147. 147. M. Otsuka, F. Kato and Y. Matsuda, Comparative evaluation of the degree of indomethacin crystallinity by chemoinfometrical Fourier-transformed near-infrared spectroscopy and conventional powder X-ray diffractometry,(2000) E9; DOI: 10.1208/ps020109.
  148. 148. P. Vandenabeele,, Wiley, Chichosten 2013, pp. 23-80.
  149. 149. P. Karmwar, K. Graeser, K. C. Gordon, C. J. Strachan and T. Rades, Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin,(2012) 459-464; DOI: 10.1016/j.ejpb.2011.10.006.
  150. 150. J. P. Boetker, V. Koradia, T. Rades and J. Rantanen, Atomic pairwise distribution function analysis of the amorphous phase prepared by different manufacturing routes,(2012) 93-103 DOI: 10.3390/pharmaceutics4010093.
  151. 151. M. Savolainen, K. Kogermann, A. Heinz, J. Aaltonen, L. Peltonen, C. Strachan and J. Yliruusi, Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy,(2009) 71-79; DOI: 10.1016/j.ejpb. 2008.06.001.
  152. 152. S. Hasegawa, T. Hamaura, N. Furuyama, S. Horikawa, A. Kusai, E. Yonemochi and K. Terada, Uniformity and physical states of troglitazone in solid dispersions determined by electron probe microanalysis and microthermal analysis,(2004) 39-46; DOI: 10.1016/j. ijpharm.2004.04.024.
  153. 153. K. Kawakami, T. Numa and Y. Ida, Assessment of amorphous content by microcalorimetry,(2002) 417-423; DOI: 10.1002/jps.10017.
  154. 154. G. Buckton, P. Darcy, D. Greenleaf and P. Holbrook, The use of isothermal microcalorimetry in the study of changes in crystallinity of spray-dried salbutamol sulphate,(1995) 113-118; DOI: 10.1016/0378-5173(94)00322-V.
  155. 155. L. E. Briggner, G. Buckton, K. Bystrom and P. Darcy, The use of isothermal microcalorimetry in the study of changes in crystallinity induced during the processing of powders,(1994) 125-135; DOI: 10.1016/0378-5173(94)90458-8.
  156. 156. D. Giron, P. Remy, S. Thomas and E. Vilette, Quantitation of amorphicity by microcalorimetry,(1997) 465-472; DOI: 10.1007/BF01979493.
  157. 157. J. Nishizawa, N. G. Hadjiconstantinou, G. Dimonte, P. S. Lomdahl, B. L. Holian and B. J. Alder, Pioneering work of THz wave and its application for molecular sciences,(2004) 369-375.
DOI: https://doi.org/10.2478/acph-2013-0026 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 305 - 334
Published on: Oct 22, 2013
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Related subjects:

© 2013 Tomaž Einfalt, Odon Planinšek, Klemen Hrovat, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.